GPC3 and neoplasm: In this preclinical study, we report the ability of a novel radioimmunotherapy agent, combining the radionuclide 90Y with an HCC-specific antibody targeting the cell surface proteoglycan GPC3, to halt tumor growth in an orthotopic xenograft model.